Intravenous therapy

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

Retrieved on: 
화요일, 5월 7, 2024
Cancer, FOLFIRINOX, Safety, Pancreatic cancer, Research, Irinotecan, Cell, HCT, Phase II, SJD, Intravenous therapy, ASCO, Therapy, Science, Vice, Patient, Gene, Society, IDMC, GMP, Clinical trial, Annual general meeting, Pharmaceutical industry

ROCKVILLE, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • The trial is expected to enroll 92 evaluable patients and is expected to complete enrollment in the third quarter of 2024.
  • The trial has completed enrollment into the second cohort and a data readout are expected in the third quarter of 2024.
  • First Quarter Ended March 31, 2024 Financial Results
    General and administrative expenses decreased to $1.9 million for the three months ended March 31, 2024, from $2.2 million for the three months ended March 31, 2023.
  • Cash and cash equivalents totaled $18.3 million as of March 31, 2024, compared to $23.2 million as of December 31, 2023.

CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

Retrieved on: 
화요일, 4월 30, 2024
University of Southern California, Efficacy, University, UCSD, Radiation, Resection, Regenerative medicine, HGG, TMZ, Doctor of Philosophy, RRV, GBM, WGS, Glioblastoma, Artificial intelligence, Depression, CIRM, UCSF, USC, Intravenous therapy, Neoplasm, Clinical trial, Medicine, SHROOM3, Whole genome sequencing, SAN, Medical imaging

We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.

Key Points: 
  • We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.
  • DB107 consists of two components: DB107–RRV (vocimagene amiretrorepvec) as a prodrug activator gene therapy and DB107–FC (extended-release 5–fluorocytosine [5–FC]) as an oral prodrug.
  • Retrospective analysis of an earlier randomized clinical trial in patients with recurrent HGG suggested improved overall survival in DGM7–positive patients treated with DB107.
  • "We are excited to conduct this novel trial which will be investigating several new approaches for the first time in patients with newly–diagnosed high–grade glioma.

Dr. Golberg Institute of Functional and Aesthetic Medicine Announces Partnership with Casa Cipriani

Retrieved on: 
금요일, 4월 19, 2024
Relaxation, Rejuvenation, Intravenous therapy, Health, Partnership, Battery Maritime Building, Casa Cipriani, Functional, Patient, Medicine

New York, New York--(Newsfile Corp. - April 19, 2024) - New York City's medical and hospitality scenes unite as the esteemed Dr. Golberg Institute of Functional & Aesthetic Medicine unveils its partnership with Casa Cipriani.

Key Points: 
  • New York, New York--(Newsfile Corp. - April 19, 2024) - New York City's medical and hospitality scenes unite as the esteemed Dr. Golberg Institute of Functional & Aesthetic Medicine unveils its partnership with Casa Cipriani.
  • With this partnership, Casa Cipriani members and hotel guests alike will have access to services such as custom IVs, medical concierge services, and non-surgical aesthetics.
  • The partnership with the Dr. Golberg Institute further solidifies Casa Cipriani's commitment to offering guests a complete wellness experience.
  • As the collaboration between the Dr. Golberg Institute of Functional & Aesthetic Medicine and Casa Cipriani takes shape, patients can look forward to a new level of luxury and sophistication in their healthcare journey.

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Retrieved on: 
월요일, 3월 25, 2024
Research, SJD, IDMC, Conference call, Conference, Retinoblastoma, Telephone, Patient, Acquisition, Cancer, VCN, Insurance, Bank statement, GMP, Clinical trial, Safety, Sant Joan, Therapy, Intravenous therapy, HCT, Pharmaceutical industry

ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the full-year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • The trial is expected to enroll 92 evaluable patients and remains on track to complete enrollment in H1 2024.
  • Other income for the year ended December 31, 2023 is primarily comprised of interest income of $1,439,000 and an exchange gain of $3,000.
  • Cash and cash equivalents totaled $23.2 million as of December 31, 2023, compared to $41.8 million as of December 31, 2022.
  • ET to discuss its financial results for the full-year ended December 31, 2023 and provide a corporate update.

Revive Drip’s Expert IV Nurses Bring Alternative Wellness Solutions to the Greater Puget Sound Area

Retrieved on: 
월요일, 3월 25, 2024
RN, Headache, Puget Sound, Nutrient, Pound, GIG, COVID-19, Patient, Trauma, Migraine, Suite, Dehydration, Nurse practitioner, Injection, Safety, Intravenous therapy, Collection, ARNP, Nursing

GIG HARBOR, WA, March 25, 2024 (GLOBE NEWSWIRE) -- Revive Drip, a leading mobile intravenous therapy (IV) company providing customized hydration and immune-boosting therapy throughout the Puget Sound, announced today the opening of the company’s brick-and-mortar clinic in Gig Harbor, Washington. The company’s expansion marks an exciting milestone for Revive Drip, delivering expert relief through progressive IV hydration for customers seeking alternative medical solutions.

Key Points: 
  • The company’s expansion marks an exciting milestone for Revive Drip, delivering expert relief through progressive IV hydration for customers seeking alternative medical solutions.
  • Since 2021, Revive Drip has been providing convenient and effective solutions tailored to their client’s specific wellness needs within the comfort of their client’s homes.
  • We provide expert nursing assessment skills combined with hydration and immune support for temporary relief,” explained Laura Ude, RN and Chief Operating Officer of Revive Drip.
  • Our services particularly benefit clients with autoimmune diseases, chronic headaches, and those seeking alternative solutions to the traditional medical system.

Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting

Retrieved on: 
수요일, 3월 13, 2024
Safety, Annual general meeting, Poster, ASX, RCE, Society, Intravenous therapy

SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a poster presentation of data from a Phase 1 study evaluating the safety of its lead asset, RECCE® 327, at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting taking place March 27-29, 2024, in Colorado Springs, Colorado.

Key Points: 
  • SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a poster presentation of data from a Phase 1 study evaluating the safety of its lead asset, RECCE® 327, at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting taking place March 27-29, 2024, in Colorado Springs, Colorado.
  • Details for the presentation are as follows:
    Title: FIH Study of Intravenous RECCE 327: A Novel, Broad Spectrum, Synthetic Anti-Infective
    A copy of the poster will be available on Recce’s website after the conclusion of the conference.

OptionMetrics Releases IvyDB US 6.0 and IvyDB ETF 4.0 with Proprietary Methodologies for Faster, More Precise Options Implied Volatilities

Retrieved on: 
수요일, 3월 13, 2024
Research, Technology, Finance, Fintech, Consulting, Professional Services, Software, Data Analytics, Data Management, Science, Microsoft, Methodology, Prevalence, SQL, Name, Jinn, Risk, Linux, PostgreSQL, 4.0, Index, Intravenous therapy, Data management, Computer data storage

OptionMetrics , the leader in financial data and analytics for institutional investors and academic researchers worldwide, releases IvyDB US 6.0 and IvyDB ETF 4.0 .

Key Points: 
  • OptionMetrics , the leader in financial data and analytics for institutional investors and academic researchers worldwide, releases IvyDB US 6.0 and IvyDB ETF 4.0 .
  • In order to better serve its customers amid economic shifts, the prevalence of meme stocks, and need for highly accurate implied volatility calculations to measure risk, OptionMetrics has significantly enhanced its historical end-of-day options data .
  • Improved Index Volatilities – enhances the term structure in option pricing models to produce even more accurate index options vols, implied volatilities, and greeks, and reflection of market conditions.
  • Precise Single Stock Volatilities with Implied Borrowing Costs – for even greater accuracy in put-call IV spreads across the entire universe of single stocks.

New Survey Reveals Patients Receive Too Many Needlesticks

Retrieved on: 
수요일, 3월 27, 2024
Health, The Harris Poll, Risk, BDX, Patient, Hospital, RNS, Standard of care, United, Needle, Intravenous therapy, Nursing

FRANKLIN LAKES, N.J., March 27, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a new survey conducted by The Harris Poll that reveals that many patients receive too many needlesticks in hospital procedures and amplifies misconceptions and lack of awareness from Americans on the risks of common medical procedures.

Key Points: 
  • Needlesticks are an often-overlooked challenge but can be one of the most traumatic aspects of a patient's hospital stay.
  • Moreover, 77% of patients are unaware that regardless of what conditions they may have, patients should expect no more than two needlestick attempts from one clinician.
  • Unsurprisingly, the survey highlights strong concern from nurses on the impact of repeated needlesticks to the patient care experience.
  • A strong majority of nurses agree that repeated needlesticks negatively impact the patient experience and say that alternatives are needed to reduce the number of needlesticks patients encounter (92% and 91%, respectively).

ALIVE AND WELL ANNOUNCES NEW LOCATION IN BOULDER

Retrieved on: 
목요일, 3월 21, 2024
Well, Ozone, Disease, Patient, Inflammation, Knowledge, Sleep, Dermatology, Immunity, Pediatrics, Intravenous therapy, Immune system, Therapy, FDA, Alive, NAD, Food

AUSTIN, Texas, March 21, 2024 /PRNewswire/ -- Alive and Well, an integrative wellness center, plans to open its newest location in early April in Boulder, Colorado. The new 3,800-square-foot space will be located at the Ideal Broadway Shops.

Key Points: 
  • AUSTIN, Texas, March 21, 2024 /PRNewswire/ -- Alive and Well , an integrative wellness center, plans to open its newest location in early April in Boulder, Colorado.
  • Alive and Well combines traditional practices with cutting-edge therapies by offering a functional medicine clinic, IV therapy, professional-grade supplements, natural beauty products and a compounding pharmacy.
  • * Alive and Well also offers ozone insufflations, which can support the immune system, fight infections, reduce inflammation and increase oxygenated blood flow.
  • To learn more about Alive and Well and its services, visit Instagram , Facebook , TikTok , YouTube and online at www.aliveandwell.health .

DripDrop® Hydration Launches New Brand Campaign "Gotta Have My Drip"

Retrieved on: 
목요일, 3월 14, 2024
Absorption, Taste, SAN, Social media, Perspiration, Professional corporation, Life, Dehydration, Water, Intravenous therapy, Mission, Firefighter, CMO, Movement

SAN FRANCISCO, March 14, 2024 /PRNewswire/ -- DripDrop®, the fast-growing electrolyte drink mix that offers the fastest way to hydrate, has launched its new brand campaign, "Gotta Have My Drip".  The digital-first campaign underscores the importance of proper hydration and features a series of content showcasing people on a mission who want to perform at their mental and physical best. Following the launch of the "Gotta Have My Drip" creative online, partnerships with a variety of social media influencers will further amplify the campaign's reach.

Key Points: 
  • The digital-first campaign underscores the importance of proper hydration and features a series of content showcasing people on a mission who want to perform at their mental and physical best.
  • "DripDrop has long been trusted and used by professional athletes, firefighters, the U.S. military, medical professionals, and people who recognize the importance of proper hydration to perform at their best."
  • Its unique formula delivers fast hydration with 3 times more sodium electrolytes and half the sugar of the leading sports drink, plus essential vitamins for optimized daily hydration and wellness.
  • What we're made of matters:
    DripDrop is available at DripDrop.com and at Amazon.com as well as many retailers throughout the country.